Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion
Lilly will pay $100 million upfront to work with the Beijing-based biotech on as many as five undisclosed drug targets
We haven't written up this one. Quartz has the full story — the link below goes straight to it.